Elan forecasts rare profit for 2010

Increased demand for its multiple sclerosis drug Tysabri and a tie-up with Johnson & Johnson helped trim losses at Elan, leading the Irish pharma to predict that in 2010, it would make an operating profit for the first time in nine years. Report